JP2011518119A - ４−フェニル酪酸（４ｐｂａ）およびその医薬上許容し得る塩についての新規用途 - Google Patents

４−フェニル酪酸（４ｐｂａ）およびその医薬上許容し得る塩についての新規用途 Download PDF

Info

Publication number
JP2011518119A
JP2011518119A JP2010550224A JP2010550224A JP2011518119A JP 2011518119 A JP2011518119 A JP 2011518119A JP 2010550224 A JP2010550224 A JP 2010550224A JP 2010550224 A JP2010550224 A JP 2010550224A JP 2011518119 A JP2011518119 A JP 2011518119A
Authority
JP
Japan
Prior art keywords
4pba
disease
alzheimer
pharmaceutically acceptable
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010550224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518119A5 (enExample
Inventor
ディアナ・サラ・フレチリャ・マンソ
アナ・マリア・ガルシア・オスタ
ルイス・アルベルト・ペレス・メディアビリャ
アナ・ロウルデス・リコバラサ・アバルケロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Publication of JP2011518119A publication Critical patent/JP2011518119A/ja
Publication of JP2011518119A5 publication Critical patent/JP2011518119A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2010550224A 2008-03-13 2009-03-06 ４−フェニル酪酸（４ｐｂａ）およびその医薬上許容し得る塩についての新規用途 Withdrawn JP2011518119A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200800736 2008-03-13
ES200800736A ES2332687B1 (es) 2008-03-13 2008-03-13 Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
PCT/ES2009/000121 WO2009112609A1 (es) 2008-03-13 2009-03-06 Nuevos usos del 4-fenilbutirato de sodio (4 pba) y sus sales farmacéuticamente aceptables

Publications (2)

Publication Number Publication Date
JP2011518119A true JP2011518119A (ja) 2011-06-23
JP2011518119A5 JP2011518119A5 (enExample) 2012-04-26

Family

ID=40691368

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010550224A Withdrawn JP2011518119A (ja) 2008-03-13 2009-03-06 ４−フェニル酪酸（４ｐｂａ）およびその医薬上許容し得る塩についての新規用途

Country Status (11)

Country Link
US (1) US20110027251A1 (enExample)
EP (1) EP2272515A1 (enExample)
JP (1) JP2011518119A (enExample)
CN (1) CN102036665A (enExample)
AU (1) AU2009224613A1 (enExample)
BR (1) BRPI0909745A2 (enExample)
CA (1) CA2718463A1 (enExample)
ES (1) ES2332687B1 (enExample)
MX (1) MX2010009933A (enExample)
RU (1) RU2010138638A (enExample)
WO (1) WO2009112609A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016515575A (ja) * 2013-03-24 2016-05-30 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 細胞生存率を向上させるための組成物およびその使用方法
WO2017159484A1 (ja) * 2016-03-18 2017-09-21 学校法人同志社 ２，４－ジアミノフェノール誘導体、及び、タウ及び／又はアミロイドβの凝集阻害剤
JP2019214546A (ja) * 2018-06-11 2019-12-19 学校法人福岡大学 終末糖化産物生成抑制剤及び医薬組成物
JP2022140556A (ja) * 2018-11-27 2022-09-26 国立研究開発法人農業・食品産業技術総合研究機構 ケミカルシャペロンまたは神経細胞死の抑制剤
US11559533B2 (en) 2019-12-16 2023-01-24 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
US12138272B2 (en) 2022-05-12 2024-11-12 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080827A1 (es) * 2010-04-06 2012-05-09 Bayer Cropscience Ag Utilizacion del acido 4- fenil- butirico y/o de sus sales para el aumento de la tolerancia al estres en plantas
CN101973868B (zh) * 2010-11-12 2012-08-15 北京恒瑞康达医药科技发展有限公司 苯丁酸钠ⅰ型结晶及其制备方法
EP2599479A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-phenylbutyric acid for the treatment of alzheimer's disease
WO2013149091A1 (en) 2012-03-29 2013-10-03 The Regents Of The University Of Colorado, A Body Corporate Composition and method for treating neurodegenerative disease
CN102757334B (zh) * 2012-07-30 2014-05-28 北京恒瑞康达医药科技发展有限公司 苯丁酸钠ⅱ型晶体及其制备方法
EP3019865A4 (en) * 2013-07-12 2017-04-05 Immuneering Corporation Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
US11224668B2 (en) * 2016-02-29 2022-01-18 Neurovation Labs, Inc. Compositions and methods to detect GluA1 in brain and to identify the presence of GluA1-mediated PTSD
IL296490B1 (en) 2016-03-15 2025-09-01 Acer Therapeutics Inc Tasty compositions containing sodium phenylbutyrate and their uses
WO2020139874A1 (en) * 2018-12-27 2020-07-02 Virginia Polytechnic Institute And State University Chemically programmed neutrophils and uses thereof
US20240108593A1 (en) * 2020-12-07 2024-04-04 University Of Miami Method of treating polyamine imbalance-related disorders
JP2024543053A (ja) * 2021-11-08 2024-11-19 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 神経変性疾患の治療のための胆汁酸及びフェニルブチレート化合物の組合せ
CN116099003A (zh) * 2022-11-28 2023-05-12 核工业总医院 内质网应激抑制剂在放射性认知功能障碍药物中的应用
WO2024165757A1 (en) 2023-02-10 2024-08-15 Ludwig-Maximilians-Universität München Oral phenylbutyrate for treatment of human 4-repeat tauopathies
CN117338763A (zh) * 2023-11-01 2024-01-05 重庆医科大学 丁酸钠在制备治疗帕金森病的药物中的应用及其治疗新靶标

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
DE69706566T2 (de) * 1996-08-13 2002-07-11 P.N. Gerolymatos S.A., Kruoneri Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US6664297B1 (en) * 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
WO2002090534A1 (en) * 2001-05-02 2002-11-14 The Regents Of The University Of California Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors
EP1482962A4 (en) * 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
WO2009133128A1 (en) * 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7080944B2 (ja) 2013-03-24 2022-06-06 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 細胞生存率を向上させるための組成物およびその使用方法
JP2023085274A (ja) * 2013-03-24 2023-06-20 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 細胞生存率を向上させるための組成物およびその使用方法
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
US12186330B2 (en) 2013-03-24 2025-01-07 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
US10251896B2 (en) 2013-03-24 2019-04-09 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
JP2019123721A (ja) * 2013-03-24 2019-07-25 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 細胞生存率を向上させるための組成物およびその使用方法
JP7596421B2 (ja) 2013-03-24 2024-12-09 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 細胞生存率を向上させるための組成物およびその使用方法
US10857162B2 (en) 2013-03-24 2020-12-08 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
JP2021008473A (ja) * 2013-03-24 2021-01-28 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 細胞生存率を向上させるための組成物およびその使用方法
JP2016515575A (ja) * 2013-03-24 2016-05-30 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 細胞生存率を向上させるための組成物およびその使用方法
JP7242945B2 (ja) 2013-03-24 2023-03-20 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 細胞生存率を向上させるための組成物およびその使用方法
JP2022122929A (ja) * 2013-03-24 2022-08-23 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 細胞生存率を向上させるための組成物およびその使用方法
US11071742B2 (en) 2013-03-24 2021-07-27 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
WO2017159484A1 (ja) * 2016-03-18 2017-09-21 学校法人同志社 ２，４－ジアミノフェノール誘導体、及び、タウ及び／又はアミロイドβの凝集阻害剤
JPWO2017159484A1 (ja) * 2016-03-18 2019-01-24 学校法人同志社 ２，４−ジアミノフェノール誘導体、及び、タウ及び／又はアミロイドβの凝集阻害剤
JP2019214546A (ja) * 2018-06-11 2019-12-19 学校法人福岡大学 終末糖化産物生成抑制剤及び医薬組成物
JP2022140556A (ja) * 2018-11-27 2022-09-26 国立研究開発法人農業・食品産業技術総合研究機構 ケミカルシャペロンまたは神経細胞死の抑制剤
JP7343118B2 (ja) 2018-11-27 2023-09-12 国立研究開発法人農業・食品産業技術総合研究機構 ケミカルシャペロンまたは神経細胞死の抑制剤
US11559533B2 (en) 2019-12-16 2023-01-24 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
US12246027B2 (en) 2019-12-16 2025-03-11 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
US12138272B2 (en) 2022-05-12 2024-11-12 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
US20110027251A1 (en) 2011-02-03
CN102036665A (zh) 2011-04-27
WO2009112609A1 (es) 2009-09-17
CA2718463A1 (en) 2009-09-17
ES2332687A1 (es) 2010-02-10
BRPI0909745A2 (pt) 2019-09-24
MX2010009933A (es) 2010-12-06
RU2010138638A (ru) 2012-04-20
ES2332687B1 (es) 2011-01-10
EP2272515A1 (en) 2011-01-12
AU2009224613A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
JP2011518119A (ja) ４−フェニル酪酸（４ｐｂａ）およびその医薬上許容し得る塩についての新規用途
JP6395838B2 (ja) 神経疾患の処置のためのトラセミド及びバクロフェンを含む組成物
KR101611824B1 (ko) 세포 스트레스 반응 조절을 통한 알츠하이머 질환 및 관련 장애의 치료를 위한 신규 치료학적 접근법
Parry et al. Functional amyloid signaling via the inflammasome, necrosome, and signalosome: new therapeutic targets in heart failure
JP7365426B2 (ja) 精神障害、行動障害、認知障害を処置するための医薬組成物及び方法
Chen et al. Maraviroc, an inhibitor of chemokine receptor type 5, alleviates neuroinflammatory response after cerebral Ischemia/reperfusion injury via regulating MAPK/NF-κB signaling
Wang et al. Exendin‑4 antagonizes Aβ1‑42‑induced attenuation of spatial learning and memory ability
US20120316247A1 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
WO2019205748A1 (zh) 一种化合物在抑制A β蛋白聚积治疗老年痴呆方面的应用
US9931326B2 (en) Composition comprising torasemide and baclofen for treating neurological disorders
AU2024202516A1 (en) Pharmaceutical combination and its use for treating synucleinopathies
JP7249433B2 (ja) 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物
CA3099090A1 (en) Pharmaceutical combinations of zonisamide and praxipexole, and related methods, for treating synucleinopathies
KR20230013116A (ko) 신경보호 유도용 화합물 및 조성물
JP2023501151A (ja) 神経変性疾患及び／又はその臨床的状態を抑制及び／又は治療するための組成物及び方法
JP6429401B2 (ja) 変異を有するｉ型コラーゲンの小胞体内過剰蓄積正常化剤
US20160136229A1 (en) Materials for positive cathepsin b modulation and methods of use for treating mild cognitive impairment (mci), early dementia, a-synucleinopathy, traumatic brain injury, cardiomyopathy, eye disease and skin damage
WO2024165757A1 (en) Oral phenylbutyrate for treatment of human 4-repeat tauopathies
JP2022517734A (ja) ドンペリドン抗神経変性剤の組み合わせと使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120306

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120626